ÂÜÀòÂÒÂ×

Stephanie Saddic is a seasoned professional in the field of gene therapy and biopharmaceuticals, currently serving as Director and Technical Program Leader at Novartis Gene Therapies since January 2023, overseeing complex CMC matrix teams for AAV gene therapy program development. Prior to this, Stephanie held the position of Senior Director at Gyroscope Therapeutics from September 2019 to December 2022, managing CMC matrix workstreams for multiple AAV gene therapy initiatives. With extensive experience at GSK from 2006 to 2019, roles included Scientific Leader for cell and gene therapy projects and CMC Leader for a commercially approved monoclonal antibody. Earlier career experience includes significant contributions at Centocor and Charles River Laboratories in quality control and laboratory settings. Stephanie holds an Executive MBA from Quantic School of Business and Technology and a Bachelor of Science in Biology from Salisbury University.